Among the various subtypes of NSCLC, mutations in the epidermal growth factor receptor (EGFR) gene play a crucial role in lung tumorigenesis, making EGFR a primary therapeutic target [2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.